VIDEO | 02:10
Neuro-oncologist Ingo Mellinghoff, MD, FACP discusses how his research has led to a new targeted therapy for IDH-mutant glioma – and details how this may mark a paradigm shift in therapeutic options for patients with brain tumors.
Neuro-oncologist Ingo Mellinghoff, MD, FACP discusses how his research has led to a new targeted therapy for IDH-mutant glioma – and details how this may mark a paradigm shift in therapeutic options for patients with brain tumors.
